HPMA copolymer conjugates for dual therapy

    loading  Checking for direct PDF access through Ovid


The synthesis and physico-chemical and biological properties of new HPMA-based polymer conjugates intended for combination cancer chemotherapy are described. These polymer conjugates contain either two drugs of different specificity, doxorubicin (Dox) and dexamethasone (Dex), both bound to the same polymer or combination of differently attached Dox, via pH-sensitive hydrazone linkage or tetrapeptide spacer (GFLG). All the conjugates are relatively stable at pH 7.4 (blood pH) but release the drugs in the presence of lysosomal enzymes or under mild acidic conditions.

    loading  Loading Related Articles